-
公开(公告)号：US06548490B1
公开(公告)日：2003-04-15
申请号：US09467094
申请日：1999-12-10
IPC分类号： A61K3156
CPC分类号： A61K9/0034 , A61K9/0031 , A61K9/0056 , A61K9/006 , A61K31/00 , A61K31/343 , A61K31/381 , A61K31/40 , A61K31/4015 , A61K31/4164 , A61K31/4166 , A61K31/426 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4704 , A61K31/4709 , A61K31/4745 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/505 , A61K31/519 , A61K31/52 , A61K31/522 , A61K31/538 , A61K31/549 , A61K31/5513 , A61K45/06
摘要： A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the transmucosal administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, within the context of an effective dosing regimen. Preferred modes of administration include transbuccal, sublingual and transrectal routes. Pharmaceutical formulations and kits are provided as well.
-
2.发明授权Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation 失效施用5-HT受体激动剂和拮抗剂，以治疗早泄公开(公告)号：US06228864B1
公开(公告)日：2001-05-08
申请号：US09181071
申请日：1998-10-27
IPC分类号： A61K3144
CPC分类号： A61K31/00 , A61F5/41 , A61K9/0034 , A61K31/135 , A61K31/137 , A61K31/357 , A61K31/4045 , A61K31/4178 , A61K31/4468 , A61K31/517 , A61K31/519 , A61K31/551 , A61K31/5513 , A61K45/06 , A61M31/00
摘要： A method is provided for delaying the onset of ejaculation in an individual. The method preferably involves administration of an antidepressant drug, a serotonin agonist or antagonist, an adrenergic agonist or antagonist, an adrenergic neurone blocker, or a derivative analog thereof, within the context of an effective dosing regimen. The preferred mode of administration is transurethral; however, the selected active agent may also be delivered via intracavernosal injection or using alternative routes. Pharmaceutical formulations and kits are provided as well.
摘要翻译： 提供了一种用于延迟个体射精发作的方法。 所述方法优选包括在有效给药方案的上下文中施用抗抑郁药物，5-羟色胺激动剂或拮抗剂，肾上腺素能激动剂或拮抗剂，肾上腺素能神经元阻滞剂或其衍生物类似物。 优选的给药方式是经尿道; 然而，所选择的活性剂也可以通过海绵体内注射或使用替代途径递送。 还提供药物制剂和试剂盒。
-
3.发明授权公开(公告)号：US06403597B1
公开(公告)日：2002-06-11
申请号：US09888250
申请日：2001-06-21
申请人： Leland F. Wilson , Paul C. Doherty, Jr. , Virgil A. Place , William L. Smith , Ibrahim AbouBakr Abdel-Hamid Abdou Ali
发明人： Leland F. Wilson , Paul C. Doherty, Jr. , Virgil A. Place , William L. Smith , Ibrahim AbouBakr Abdel-Hamid Abdou Ali
IPC分类号： A61K3150
CPC分类号： A61K9/0031 , A61K9/0056 , A61K9/006 , A61K31/00 , A61K31/343 , A61K31/381 , A61K31/40 , A61K31/4015 , A61K31/4164 , A61K31/4166 , A61K31/426 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4704 , A61K31/4709 , A61K31/4745 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/505 , A61K31/519 , A61K31/52 , A61K31/522 , A61K31/538 , A61K31/549 , A61K31/5513 , A61K45/06
摘要： A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as “as needed” basis, i.e., the drug is administered immediately or several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided.
摘要翻译： 提供了通过施用磷酸二酯酶抑制剂例如III型，IV型或V型磷酸二酯酶的抑制剂来治疗早泄的方法。 在优选的实施方案中，施用是“根据需要”的基础，即药物在性活动之前立即或几小时施用。 还提供药物制剂和包装试剂盒。
-
4.发明授权Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction 有权局部给予IV型磷酸二酯酶抑制剂治疗勃起功能障碍
公开(公告)号：US6127363A
公开(公告)日：2000-10-03
申请号：US437999
申请日：1999-11-10
IPC分类号： A61K9/02 , A61K31/00 , A61K31/343 , A61K31/381 , A61K31/4015 , A61K31/4164 , A61K31/4166 , A61K31/426 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/47 , A61K31/4704 , A61K31/4709 , A61K31/4745 , A61K31/485 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/522 , A61K31/5377 , A61K31/538 , A61K31/549 , A61K31/5513 , A61K45/00 , A61K45/06 , A61P15/10 , A61K31/55
CPC分类号： A61K9/0034 , A61K31/00 , A61K31/343 , A61K31/381 , A61K31/4015 , A61K31/4164 , A61K31/4166 , A61K31/426 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4704 , A61K31/4709 , A61K31/4745 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/519 , A61K31/52 , A61K31/522 , A61K31/538 , A61K31/549 , A61K31/5513 , A61K45/06
摘要： A method is provided for treating erectile dysfunction, e.g., vasculogenic erectile dysfunction such as vasculogenic impotence. The method involves the administration of a Type IV phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, wherein administration is local, i.e., transurethral, intracavernosal, topical or transdermal. A preferred mode of administration is transurethral. Pharmaceutical formulations and kits are provided as well.
摘要翻译： 提供了一种治疗勃起功能障碍的方法，例如血管发生勃起功能障碍如血管发生性阳。。 该方法包括施用IV型磷酸二酯酶抑制剂或其药学上可接受的盐，酯，酰胺或其衍生物，其中给药是局部的，即经尿道，海绵体内，局部或透皮。 优选的给药方式是经尿道。 还提供药物制剂和试剂盒。
-
5.发明授权Administration of 5-HT.sub.3 receptor antagonists to treat premature ejaculation 失效施用5-HT 3受体拮抗剂治疗早泄
公开(公告)号：US6037360A
公开(公告)日：2000-03-14
申请号：US959061
申请日：1997-10-28
IPC分类号： A61F5/41 , A61K9/00 , A61K31/00 , A61K31/135 , A61K31/137 , A61K31/357 , A61K31/4045 , A61K31/4178 , A61K31/4468 , A61K31/517 , A61K31/519 , A61K31/551 , A61K31/5513 , A61K45/06 , A61K31/415 , A61K31/405
CPC分类号： A61K31/00 , A61F5/41 , A61K31/135 , A61K31/137 , A61K31/357 , A61K31/4045 , A61K31/4178 , A61K31/4468 , A61K31/517 , A61K31/519 , A61K31/551 , A61K31/5513 , A61K45/06 , A61K9/0034 , A61M31/00 , A61M35/00
摘要： A method is provided for delaying the onset of ejaculation in an individual. The method involves administration of a 5-HT.sub.3 receptor antagonist within the context of an effective dosing regimen. The preferred mode of administration is transurethral; however, the selected inhibitor may also be delivered via intracavernosal injection or using alternative routes.
摘要翻译： 提供了一种用于延迟个体射精发作的方法。 该方法包括在有效给药方案的上下文中施用5-HT 3受体拮抗剂。 优选的给药方式是经尿道; 然而，所选择的抑制剂也可以通过海绵体内注射或使用替代途径递送。
-
6.发明授权Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction 有权局部给予III型磷酸二酯酶抑制剂治疗勃起功能障碍
公开(公告)号：US6156753A
公开(公告)日：2000-12-05
申请号：US437682
申请日：1999-11-10
IPC分类号： A61K9/02 , A61K31/00 , A61K31/343 , A61K31/381 , A61K31/4015 , A61K31/4164 , A61K31/4166 , A61K31/426 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/47 , A61K31/4704 , A61K31/4709 , A61K31/4745 , A61K31/485 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/522 , A61K31/5377 , A61K31/538 , A61K31/549 , A61K31/5513 , A61K45/00 , A61K45/06 , A61P15/10
CPC分类号： A61K9/0034 , A61K31/00 , A61K31/343 , A61K31/381 , A61K31/4015 , A61K31/4164 , A61K31/4166 , A61K31/426 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4704 , A61K31/4709 , A61K31/4745 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/519 , A61K31/52 , A61K31/522 , A61K31/538 , A61K31/549 , A61K31/5513 , A61K45/06
摘要： A method is provided for treating erectile dysfunction, e.g., vasculogenic erectile dysfunction such as vasculogenic impotence. The method involves the administration of a Type III phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, wherein administration is transurethral, topical or transdermal. A preferred mode of administration is transurethral. Pharmaceutical formulations and kits are provided as well.
摘要翻译： 提供了一种治疗勃起功能障碍的方法，例如血管发生勃起功能障碍如血管发生性阳。。 该方法包括施用III型磷酸二酯酶抑制剂或其药学上可接受的盐，酯，酰胺或其衍生物，其中给药是经尿道，局部或经皮。 优选的给药方式是经尿道。 还提供药物制剂和试剂盒。
-
7.发明授权Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction 有权局部给予磷酸二酯酶抑制剂治疗勃起功能障碍
公开(公告)号：US6037346A
公开(公告)日：2000-03-14
申请号：US181070
申请日：1998-10-27
IPC分类号： A61K9/02 , A61K31/00 , A61K31/343 , A61K31/381 , A61K31/4015 , A61K31/4164 , A61K31/4166 , A61K31/426 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/47 , A61K31/4704 , A61K31/4709 , A61K31/4745 , A61K31/485 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/522 , A61K31/5377 , A61K31/538 , A61K31/549 , A61K31/5513 , A61K45/00 , A61K45/06 , A61P15/10
CPC分类号： A61K9/0034 , A61K31/00 , A61K31/343 , A61K31/381 , A61K31/4015 , A61K31/4164 , A61K31/4166 , A61K31/426 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4704 , A61K31/4709 , A61K31/4745 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/519 , A61K31/52 , A61K31/522 , A61K31/538 , A61K31/549 , A61K31/5513 , A61K45/06
摘要： A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the local administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof within the context of an effective dosing regimen. A preferred mode of administration is transurethral. Pharmaceutical formulations and kits are provided as well.
摘要翻译： 提供一种用于治疗哺乳动物男性个体勃起功能障碍的方法。 该方法包括在有效给药方案的范围内局部施用磷酸二酯酶抑制剂或其药学上可接受的盐，酯，酰胺或其衍生物。 优选的给药方式是经尿道。 还提供药物制剂和试剂盒。
-
公开(公告)号：US06472434B1
公开(公告)日：2002-10-29
申请号：US09539737
申请日：2000-03-30
申请人： Virgil A. Place , Leland F. Wilson , Paul C. Doherty, Jr. , Mark S. Hanamoto , Alfred P. Spivack , Neil Gesundheit , Sean R. Bennett
发明人： Virgil A. Place , Leland F. Wilson , Paul C. Doherty, Jr. , Mark S. Hanamoto , Alfred P. Spivack , Neil Gesundheit , Sean R. Bennett
IPC分类号： A61K3119
CPC分类号： B82Y5/00 , A61K9/0034 , A61K9/02 , A61K31/00 , A61K31/15 , A61K31/21 , A61K31/295 , A61K31/48 , A61K31/5377 , A61K31/557 , A61K31/5575 , A61K31/5585 , A61K31/56 , A61K45/06 , A61K2300/00
摘要： Methods and formulations for minimizing excess collagen are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others.
摘要翻译： 提供了减少过量胶原蛋白的方法和制剂。 将配制成含有选择的血管活性剂的药物组合物施用于经历治疗的个体的阴道，外阴区域或尿道。 合适的血管活性剂是血管扩张剂，包括天然存在的前列腺素，合成的前列腺素衍生物，内皮衍生的松弛因子，血管活性肠多肽激动剂，平滑肌松弛剂，白细胞三烯抑制剂等。
-
公开(公告)号：US06306841B1
公开(公告)日：2001-10-23
申请号：US09539484
申请日：2000-03-30
申请人： Virgil A. Place , Leland F. Wilson , Paul C. Doherty, Jr. , Mark S. Hanamoto , Alfred P. Spivack , Neil Gesundheit , Sean R. Bennett
发明人： Virgil A. Place , Leland F. Wilson , Paul C. Doherty, Jr. , Mark S. Hanamoto , Alfred P. Spivack , Neil Gesundheit , Sean R. Bennett
IPC分类号： A61K31655
CPC分类号： B82Y5/00 , A61K9/0034 , A61K9/02 , A61K31/00 , A61K31/15 , A61K31/21 , A61K31/295 , A61K31/48 , A61K31/5377 , A61K31/557 , A61K31/5575 , A61K31/5585 , A61K31/56 , A61K45/06 , A61K2300/00
摘要： Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others. The formulations are also useful for preventing the occurrence of yeast infections, improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. A clitoral drug delivery device is also provided.
摘要翻译： 提供了治疗女性性功能障碍的方法和制剂。 将配制成含有选择的血管活性剂的药物组合物施用于经历治疗的个体的阴道，外阴区域或尿道。 合适的血管活性剂是血管扩张剂，包括天然存在的前列腺素，合成的前列腺素衍生物，内皮衍生的松弛因子，血管活性肠多肽激动剂，平滑肌松弛剂，白细胞三烯抑制剂等。 该制剂也可用于预防酵母菌感染的发生，改善阴道肌张力和组织健康，增强阴道润滑，并使过量的胶原蛋白沉积最小化。 还提供阴蒂药物递送装置。
-
10.发明授权Transurethral administration of vasoactive agents to treat peripheral vascular disease, related vascular diseases, and vascular impotence associated therewith 失效经尿道给药血管活性剂以治疗外周血管疾病，相关血管疾病和与之相关的血管阳。
公开(公告)号：US5919474A
公开(公告)日：1999-07-06
申请号：US959063
申请日：1997-10-28
申请人： Virgil A. Place , Mark S. Hanamoto , Paul C. Doherty, Jr. , Alfred P. Spivack , Neil Gesundheit , Sean R. Bennett
发明人： Virgil A. Place , Mark S. Hanamoto , Paul C. Doherty, Jr. , Alfred P. Spivack , Neil Gesundheit , Sean R. Bennett
CPC分类号： A61M31/007 , A61F5/41 , A61K47/10 , A61K47/34 , A61K9/0034 , A61K9/02 , A61M2210/1096
摘要： A method for treating peripheral vascular disease (PVD), related vascular diseases, and vascular impotence associated with such diseases, is provided. The method involves transurethral administration of a pharmaceutical formulation containing a selected vasoactive agent within the context of an effective dosing regimen. Preferred vasoactive agents are vasodilating agents selected from the group consisting of naturally occurring prostaglandins, synthetic prostaglandin derivatives, and combinations thereof. The pharmaceutical formulations used in conjunction with the novel method may also contain enzyme inhibitors, transurethral permeation enhancers, carriers, preservatives, surfactants, and the like. Kits and pharmaceutical formulations are provided as well.
摘要翻译： 提供了治疗与这些疾病相关的外周血管疾病（PVD），相关的血管疾病和血管阳。的方法。 该方法涉及在有效给药方案的情况下经尿道给药含有选择的血管活性剂的药物制剂。 优选的血管活性剂是选自天然存在的前列腺素，合成前列腺素衍生物及其组合的血管舒张剂。 与新方法结合使用的药物制剂还可以含有酶抑制剂，经尿道渗透促进剂，载体，防腐剂，表面活性剂等。 还提供了试剂盒和药物制剂。
-
-
-
-
-
-
-
-
-
搜索结果
51 条记录 (耗时 0.03 秒)
